CABG vs Medical Therapy for Stable Angina.
The question of whether coronary artery bypass surgery provides a survival benefit over modern medical therapy for patients with stable angina (chest pain that is predictable and occurs with exertion) has been one of the most actively debated topics in cardiovascular medicine. For decades, the assumption was that bypass surgery "fixes" blocked arteries and therefore must be superior. The reality, as illuminated by modern clinical trials, is far more nuanced. Modern medical therapy for stable coronary artery disease is remarkably effective. The combination of high-intensity statins, antiplatelet agents, beta-blockers, ACE inhibitors, and lifestyle modification can stabilize plaque, reduce inflammation, and prevent heart attacks without any invasive procedure. The question is not whether surgery works — it does — but whether it adds enough benefit over excellent medical therapy to justify the risks of surgery. This distinction is critically important because many patients with stable angina are referred for bypass surgery without a thorough trial of optimized medical therapy, and some patients undergo surgery that does not meaningfully improve their prognosis compared to medications alone.
What the evidence shows.
The ISCHEMIA trial (2020), the largest and most rigorous study addressing this question, randomized 5,179 patients with stable coronary artery disease and moderate-to-severe ischemia to an invasive strategy (CABG or PCI) plus medical therapy versus medical therapy alone. At a median follow-up of 3.2 years, there was no significant difference in the primary composite of cardiovascular death, MI, hospitalization for unstable angina, heart failure, or cardiac arrest. The invasive group experienced more periprocedural MIs (driven by PCI), while the medical therapy group had more spontaneous MIs — with no net difference in total MIs or death. However, the invasive strategy did significantly improve angina symptoms and quality of life in patients who had frequent angina at baseline. The STICH trial (CABG specifically, 10-year follow-up) showed a modest survival benefit for CABG in patients with severe LV dysfunction (EF below 35%) — suggesting that the surgical benefit is concentrated in the sickest patients, not those with preserved heart function.
Current recommendations.
Current ACC/AHA guidelines, informed by ISCHEMIA, recommend: (1) optimal medical therapy as the first-line approach for stable angina; (2) invasive revascularization (CABG or PCI) for symptom relief when angina persists despite maximally tolerated medical therapy; (3) CABG for survival benefit in specific subgroups: left main disease (above 50% stenosis), three-vessel disease with reduced LV function, and proximal LAD disease with ischemia; (4) shared decision-making with patients about the goals of revascularization — symptom relief vs. survival benefit. Surgery should not be reflexively recommended for stable angina without first optimizing medical therapy and confirming that the anatomy and clinical profile indicate a mortality benefit.
Why this matters for your decision.
Many patients are referred for CABG based on anatomy (the presence of blockages on angiography) without adequate consideration of whether medical therapy could achieve equivalent outcomes with less risk. A second opinion can determine whether the recommended surgery is for survival benefit, symptom relief, or both — and whether medical therapy has been truly optimized. This distinction prevents unnecessary surgery while identifying the patients who genuinely benefit from a surgical approach.
Need help with this decision?
Our Heart Team evaluates your specific situation with AI-augmented analysis and dual-physician review.